» Articles » PMID: 25528767

Mitochondrial P32 is Upregulated in Myc Expressing Brain Cancers and Mediates Glutamine Addiction

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Dec 22
PMID 25528767
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic reprogramming is a key feature of tumorigenesis that is controlled by oncogenes. Enhanced utilization of glucose and glutamine are the best-established hallmarks of tumor metabolism. The oncogene c-Myc is one of the major players responsible for this metabolic alteration. However, the molecular mechanisms involved in Myc-induced metabolic reprogramming are not well defined. Here we identify p32, a mitochondrial protein known to play a role in the expression of mitochondrial respiratory chain complexes, as a critical player in Myc-induced glutamine addiction. We show that p32 is a direct transcriptional target of Myc and that high level of Myc in malignant brain cancers correlates with high expression of p32. Attenuation of p32 expression reduced growth rate of glioma cells expressing Myc and impaired tumor formation in vivo. Loss of p32 in glutamine addicted glioma cells induced resistance to glutamine deprivation and imparted sensitivity to glucose withdrawal. Finally, we provide evidence that p32 expression contributes to Myc-induced glutamine addiction of cancer cells. Our findings suggest that Myc promotes the expression of p32, which is required to maintain sufficient respiratory capacity to sustain glutamine metabolism in Myc transformed cells.

Citing Articles

CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens.

Feigelson S, Dadosh T, Levi N, Sapoznikov A, Weinstein-Marom H, Blokon-Kogan D Front Immunol. 2025; 16:1398757.

PMID: 39995660 PMC: 11847833. DOI: 10.3389/fimmu.2025.1398757.


Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis.

Bi Q, Nie J, Wu Q, Sun L, Zhu S, Bai J Med Oncol. 2025; 42(3):60.

PMID: 39891862 DOI: 10.1007/s12032-025-02604-9.


Small Molecule Inhibitors of Arylamine N-Acetyltransferase 1 Attenuate Cellular Respiration.

Choudhury C, Egleton J, Butcher N, Russell A, Minchin R ACS Pharmacol Transl Sci. 2024; 7(8):2326-2332.

PMID: 39144569 PMC: 11320739. DOI: 10.1021/acsptsci.4c00282.


Novel Anthracycline Utorubicin for Cancer Therapy.

Simon-Gracia L, Sidorenko V, Uustare A, Ogibalov I, Tasa A, Tshubrik O Angew Chem Weinheim Bergstr Ger. 2024; 133(31):17155-17164.

PMID: 38505658 PMC: 10947310. DOI: 10.1002/ange.202016421.


Inhibition of Multifunctional Protein p32/C1QBP Promotes Cytostatic Effects in Colon Cancer Cells by Altering Mitogenic Signaling Pathways and Promoting Mitochondrial Damage.

Egusquiza-Alvarez C, Moreno-Londono A, Alvarado-Ortiz E, Ramos-Godinez M, Sarabia-Sanchez M, Castaneda-Patlan M Int J Mol Sci. 2024; 25(5).

PMID: 38473963 PMC: 10931692. DOI: 10.3390/ijms25052712.


References
1.
DAlessandro A, Amelio I, Berkers C, Antonov A, Vousden K, Melino G . Metabolic effect of TAp63α: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense. Oncotarget. 2014; 5(17):7722-33. PMC: 4202156. DOI: 10.18632/oncotarget.2300. View

2.
Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z . Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-88. PMC: 3221282. DOI: 10.1016/j.ccr.2011.10.015. View

3.
Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

4.
Gehart H, Kumpf S, Ittner A, Ricci R . MAPK signalling in cellular metabolism: stress or wellness?. EMBO Rep. 2010; 11(11):834-40. PMC: 2966959. DOI: 10.1038/embor.2010.160. View

5.
Cho Y, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H . Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2010; 29(11):1424-30. PMC: 3082983. DOI: 10.1200/JCO.2010.28.5148. View